Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 08, 2025 16:05 ET | Source: Annexon Biosciences Oral Presentation Features…
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
April 04, 2025 08:30 ET | Source: Xenon Pharmaceuticals Inc. Three epilepsy…